Tepnel Gets CE Mark for DNA-Based Cholesterol Test | GenomeWeb
NEW YORK (GenomeWeb News) – Tepnel Life Sciences said today that its DNA-based test for the early detection of familial hypercholesterolemia has received the CE Mark and has been commercially launched in Europe.
Manchester, England-based Tepnel said that the Elucigene FH20 kit can rapidly determine the 20 genetic mutations responsible for the disease that are most commonly found in a UK-based population.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: convergent evolution in bird hemoglobin, and more.

The Wall Street Journal speaks with patients affected by questionable test results from Theranos.

Researchers link variants in TACR3 to hot flashes during menopause, Live Science reports.

Kuwait says it will alter its law requiring citizens and visitors to provide DNA samples, New Scientist reports.